arrow
A

Alan Fix

path
H指数:28
被引数:3,238

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus subunit vaccine candidate (TV P2-VP8) in healthy Ghanaian, Malawian, and Zambian infants

安全性、免疫原性及相对效力:一种经皮三价轮状病毒亚单位疫苗候选物(TV P2-VP8)在健康加纳、马拉维和赞比亚婴儿中的表现

Vaccine
IF3.5
2025-11-290
PRE
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial

新型1型与3型口服减毒脊髓灰质炎疫苗在健康美国成年人中的安全性与免疫原性:一项首次人体、观察者设盲、多中心、第1期随机对照试验

2025-08-130
OAAI
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial
LANCET
IF88.5
2024-03-015
OAAI
Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children
2022-02-1116
OAAI
Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials

健康婴儿服用二价口服脊髓灰质炎病毒疫苗/灭活脊髓灰质炎病毒疫苗后2种新型减毒活口服脊髓灰质炎病毒2型候选疫苗的粪便脱落: 2项随机临床试验

2021-10-059
OAAI
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
LANCET
IF88.5
2021-01-0143
OAAI
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
LANCET
IF88.5
2021-01-0154
OAAI
Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial
2020-02-0176
OAAI